Condition: Premenopausal HR+/HER2- Metastatic Breast Cancer · Sponsor: Samsung Medical Center
This study is a prospective, two-arm, randomized phase II study of talazoparib versus talazoparib plus atezolizumab in ER+ premeonopausal women with metastatic breast cancer harboring HRD scar 1st line treatment: GnRH agonist + Aromatase Inhibitor(AI) + Palbociclib 28 days after the last treatment of 1st line treatment(., randomization for 2nd line treatment is conducte to arm A(Talazoparib+Atezolizumab) and arm B(Talazoparib monotherapy)
This description comes directly from the study's public registry record.
Yeon Hee Park, phD · +82-2-3410-1780 · yeonh.park@samsung.com
mieun Kim, CRA · +82 2-2148-7664 · mieun2728.kim@samsung.com
Always discuss trial participation with your own doctor first.
| Samsung medical Center | Seoul, Gannam-gu, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04819243